Teva Pharm SEC Filings

TEVA Pharmaceutical Industries (TEVA) reported an insider transaction by director Roberto Mignone. On 11/06/2025, he sold 200,000 Ordinary Shares (transaction code S) at a weighted average price of $24.1094.

Following the sale, he beneficially owned 495,000 Ordinary Shares indirectly through Swiftcurrent Master Fund Ltd. and 105,315 Ordinary Shares directly. The filing notes that TEVA’s Ordinary Shares may be represented by ADSs, each currently representing one Ordinary Share.

Teva Pharmaceutical Industries (TEVA) disclosed an insider transaction on Form 4. Chief Accounting Officer Amir Weiss sold 12,300 ordinary shares on 11/06/2025 at a weighted average price of $24.4361, with trades ranging from $24.435 to $24.455. Following the sale, he beneficially owns 17,950 shares, held directly. The filing notes that Teva’s ordinary shares may be represented by ADSs, each currently equal to one ordinary share.

TEVA: An amended Form 144 was filed for the proposed sale of 200,000 American Depositary Shares. The filing lists Piper Sandler & Co. as broker, an aggregate market value of $4,920,000, and an approximate sale date of 11/06/2025 on the NYSE.

The shares to be sold were acquired on 05/09/2018. As context, the filing reports 1,147,282,512 shares outstanding. This notice outlines a potential secondary sale by a holder and does not describe any new issuance.

Teva Pharmaceutical Industries reported Q3 2025 results showing higher profitability. Net revenues were $4,480 million, up from $4,332 million a year ago. Operating income reached $882 million versus a loss last year, and net income attributable to Teva was $433 million (basic EPS $0.38; diluted $0.37). For the first nine months, net revenues were $12,547 million with net income of $930 million.

The balance sheet reflects $2,203 million in cash and cash equivalents, total assets of $39,856 million, and Teva shareholders’ equity of $7,250 million. Senior notes and loans were $16,766 million. Teva executed several 2025 note repayments and, in May 2025, issued new senior notes of $700 million (5.75% due 2030), €1,000 million (4.125% due 2031) and $500 million (6.00% due 2032). A June 2025 tender extinguished multiple tranches, resulting in a $10 million loss recorded in financial expenses. Shares outstanding were 1,147,282,512 as of September 30, 2025.

Teva Pharmaceutical Industries (TEVA): FMR LLC filed Amendment No. 3 to its Schedule 13G reporting beneficial ownership of 24,641,361.35 TEVA common shares, representing 2.1% of the class as of 09/30/2025. FMR LLC reports sole voting power over 21,233,240.62 shares and sole dispositive power over 24,641,361.35 shares.

Abigail P. Johnson is listed with sole dispositive power over 24,641,361.35 shares and no voting power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. It also notes one or more other persons may have rights to dividends or sale proceeds, with no single person over five percent. The filer indicates ownership of five percent or less of the class.

Teva Pharmaceutical Industries Limited furnished an 8-K under Item 2.02 announcing it issued a press release with financial results for the period ended September 30, 2025. The press release is provided as Exhibit 99.1 and incorporated by reference.

The company states the information is being furnished, not filed, under the Exchange Act, which means it is not subject to Section 18 liability, unless specifically incorporated by reference elsewhere.

Harel Insurance Investments & Financial Services Ltd. reported ownership of 58,118,222 ordinary shares of Teva Pharmaceutical Industries Ltd, representing 5.1% of the class based on 1,147,150,917 shares outstanding as of June 30, 2025. Most shares are held on behalf of public clients: 56,881,124 for pooled public funds, 114,084 in third-party client accounts (with no voting power), and 1,123,014 beneficially held for Harel's own account. The filing shows shared voting power of 58,004,138 and shared dispositive power of 58,118,222. The statement clarifies these holdings are not intended to affect control of the issuer and discloses Israeli organization and office addresses.

David R. McAvoy, identified as an Executive Vice President and Chief Legal Officer of Teva Pharmaceutical Industries Ltd. (TEVA), reported an open-market purchase of 1,113 ordinary shares on 09/05/2025 at a price of $18.8572 per share. After the transaction McAvoy beneficially owns 13,027 ordinary shares. The filing notes that the ordinary shares may be represented by American Depositary Shares, each currently representing one ordinary share.

The Form 4 was signed on behalf of McAvoy by an attorney-in-fact and filed under Section 16 reporting requirements. The report contains no other derivative transactions or additional disclosures.